Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients

Background: Eculizumab blocks the lytic complement pathway by inhibiting C5 and has become the standard of care for certain complement-mediated diseases. Previously, we have shown that strong complement activation in vitro overrides the C5 inhibition by Eculizumab, which accounts for residual termin...

Full description

Bibliographic Details
Main Authors: Markus J. Harder, Britta Höchsmann, Arthur Dopler, Markus Anliker, Christof Weinstock, Arne Skerra, Thomas Simmet, Hubert Schrezenmeier, Christoph Q. Schmidt
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Immunology
Subjects:
Eculizumab
paroxysmal nocturnal hemoglobinuria
PNH
complement
residual terminal pathway activity
Coversin
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01639/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01639/full

Similar Items